Results 281 to 290 of about 8,093,285 (389)

Patient‐reported outcomes (PROs) versus patient‐reported outcome measures (PROMs)—Is there a difference? [PDF]

Clinical and Experimental Dental Research, 2018
openaire   +3 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Symptoms, side effects, quality of life and financial toxicity matter to patients with cancer, we need to do a better job of capturing and reporting these concepts in trials and clinical care

BMJ Oncology
Melanie Calvert, Roger Wilson, John Devin Peipert   +2 more
doaj   +1 more source

Patient-Reported Outcomes Measures in Spine Surgery. [PDF]

Curr Rev Musculoskelet Med
Charron B, Ross M, Thornley P.
europepmc   +1 more source

The impact of the Calman–Hine report on the processes and outcomes of care for Yorkshire's colorectal cancer patients [PDF]

, 2006
Eva Morris, Raymond Haward, Mark S. Gilthorpe, Cheryl Craigs, D Forman   +4 more
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Predictors of patient-reported outcomes phenotypes in SLE during remission: a cluster analysis approach. [PDF]

Lupus Sci Med
Elefante E, Cruz-Sanabria F, Gualtieri L, Stagnaro C, Zucchi D, Cardelli C, Signorini V, Carli L, Ferro F, Tani C, Mosca M.   +10 more
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Primary Care Patient Engagement With Patient-Reported Outcomes to Assess Osteoarthritis Symptoms. [PDF]

Arthroplast Today
Burla M, Selph TJ, Summerville FM, Bergman R, Sontag-Milobsky I, Franklin PD, Suleiman LI.   +6 more
europepmc   +1 more source

Preferring patient‐reported to observer‐reported outcomes substantially influences the results of the updated systematic review on placebos by Hróbjartsson and Gøtzsche

, 2005
Karin Meißner
openalex   +1 more source